arrow
L

Lisa A. Jackson

Kaiser Permanente Washington Health Research Institute
H指数:97
被引数:3.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The vaccine platform used for COVID-19 primary immunization shapes the quality of the human B cell response to a vaccine boost

用于COVID-19基础免疫的疫苗平台决定了人体B细胞对疫苗加强针的反应质量。

2026-02-250
PRE
Safety and immunogenicity of the Sm-p80 GLA-SE schistosomiasis vaccine

斯曼-p80 GLA-SE血吸虫病疫苗的安全性与免疫原性

2025-11-240
OAAI
Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine

疗效、免疫原性和安全性:改良型mRNA流感疫苗

2025-11-207
PRE
Near real-time surveillance and tree-based data mining to assess the safety of respiratory syncytial virus vaccines in older adults in the vaccine safety datalink

近实时监测和基于树的数据挖掘方法,用于评估疫苗安全数据链中老年人群呼吸道合胞病毒疫苗的安全性。

Vaccine
IF3.5
2025-10-240
PRE
Effect of Omicron BA.1-based compared to prototype booster mRNA vaccination on incidence of COVID-19 in the COVAIL trial

与原型加强针mRNA疫苗接种相比,Omicron BA.1基线加强针mRNA疫苗接种对COVAIL试验中COVID-19发病率的影響

Vaccine
IF3.5
2025-09-090
OAAI
Differences in influenza vaccination coverage by race and ethnicity across age groups in the Vaccine Safety Datalink, 2017–18 through 2022–23 influenza seasons

2017–18至2022–23流感季疫苗安全数据链中,不同年龄组按种族和族裔划分的流感疫苗接种覆盖率差异

Vaccine
IF3.5
2025-09-040
PRE
Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine

使用双价信使核糖核酸严重急性呼吸综合征冠状病毒2疫苗加强接种后的黏膜和系统性抗体应答

2025-04-290
PRE
Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimens

抗神经氨酸酶和抗血凝素stalk对不同流感A(H7N9)疫苗方案的反应

VACCINE
IF3.5
2025-02-010
PRE
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial
2024-09-261
PRE
Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial
2023-09-297
OAAI
Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial
2023-08-2819
OAAI
Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial
2023-08-101
OA